eXoZymes Inc. (NASDAQ:EXOZ – Get Free Report) rose 1% during trading on Tuesday . The company traded as high as $7.80 and last traded at $7.42. 2,530 shares changed hands during mid-day trading, a decline of 60% from the average daily volume of 6,279 shares. The stock had previously closed at $7.35.
Analyst Ratings Changes
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of eXoZymes in a report on Friday, May 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.
View Our Latest Report on eXoZymes
eXoZymes Trading Up 23.7%
eXoZymes (NASDAQ:EXOZ – Get Free Report) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.28) earnings per share for the quarter.
eXoZymes Company Profile
eXoZymes, Inc develops, manufactures and supplies a range of enzymes and reagents designed for molecular biology research and diagnostic applications. The company’s enzyme engineering platform underpins a portfolio of products aimed at supporting nucleic acid purification, amplification and analysis workflows.
Key offerings from eXoZymes include magnetic bead–based nucleic acid extraction kits, DNA polymerases, reverse transcriptases, proteases and custom enzyme services. In addition, the company provides molecular diagnostic test kits designed for pathogen detection, leveraging scalable production processes and quality systems aligned with regulatory standards.
eXoZymes serves academic research institutions, biotechnology and pharmaceutical companies, and clinical diagnostic laboratories worldwide.
Featured Articles
- Five stocks we like better than eXoZymes
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Receive News & Ratings for eXoZymes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for eXoZymes and related companies with MarketBeat.com's FREE daily email newsletter.
